Allogene Therapeutics Inc (ALLO)

$2.30 +0.02 (0.88%)
Market Cap 558.18M
Revenue (ttm) 0.00
Net Income (ttm) -190.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,029,800
Avg Vol 10,278,142
Day's Range N/A - N/A
Shares Out 244.82M
Stochastic %K 71%
Beta 0.46
Analysts Strong Sell
Price Target $8.65

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
Quant_Builder
Quant_Builder May. 13 at 11:45 AM
quant-builder.ai Healthcare Individual Stocks Moving - $IYH Another Model I have been trading the past couple of weeks. The IYH has been stuck at a post March low, but individuals have been moving and the sector looks like it's trying to break out. First image is picks for today and current positions. Second image its 30 day history. Avg. Confidence, Number of Picks, Equity Curve assuming 1% positions. These are part of a broader portfolio $HUM $UNH $ALLO $ELV
0 · Reply
AS1980
AS1980 May. 12 at 7:48 PM
$ALLO fckn misery
0 · Reply
BioFlare
BioFlare May. 12 at 4:03 PM
$ALLO I don't really understand why people keep complaining about the dilution still...Its done. Allo should now have money to keep it lasting for a while, bigger investors, and bigger appeal to the bigger huge bio companies. Yes, the shares were sold for 2$, but its not as if the price wasn't rolling at around 2$ before and after the dilution... At the end of the day, the early data is good. Think ahead
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 12 at 5:13 AM
$FATE had successfully treated 8+ patients in Regimen A (Less-Intensive Chemo). The outcomes here were spectacular, with patients achieving complete drug-free remissions (cures). The 100% response rate (3 out of 3) today on the first 3 patients from Regimen B (No Chemo / Background Therapy) is an absolute clinical triumph as proof of concept. With DL1 achieved a 100% response without chemo and the Phase 2 pivotal trial clearance by the FDA, hold strong and you will get rewarded. GO GO GO $FATE $ALLO $CABA $KYTX $LABU
1 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 12 at 3:51 AM
$FATE The fact that B-cell depletion lasted 12 months and occurred in secondary lymphoid tissue (nasopharyngeal) is a signature of CAR-T activity, not background steroids. The FDA's selection of Fate for the CDRP pilot suggests they are satisfied that the signal is coming from FT819, not the background drugs. Hope the management will announce that the RECLAIM-LN Phase 2 will be chemo-free and, most importantly, a registrational pivotal trial tomorrow. Cheers! $FATE $ALLO $CABA $KYTX
0 · Reply
Unburdened
Unburdened May. 11 at 4:34 PM
$ALLO Can't hold a gain if we wanted too. So glad you diluted the shit out of us for $2.00 per share. How does it feel to be A&$ F$&@!$ by Goldman and shares stolen from you?? You diluted us at $2.00 when it was trading at $2.65 BEFORE the supposed "great data". What a bunch of 🤡🤡🤡's.
0 · Reply
AS1980
AS1980 May. 11 at 1:37 PM
$ALLO why so fckn pathetic
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 11 at 1:02 PM
$FATE Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting. Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire. Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; Preclinical data for FT836 shows effective elimination of broad range of cancers in synergy with SOC treatments. Go for moon shoot $FATE !!! $CABA $ALLO $ALT $LABU
1 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 10 at 12:36 AM
$FATE A trial cannot be posted to ClinicalTrials.gov for a Phase 2 study unless the FDA has cleared the IND protocol. This means the FDA has officially authorized FATE to expand FT819 into Lupus Nephritis (LN) with a "Single-Arm" Design. While the trial is labeled "Phase 2," the single-arm nature and its timing alongside the CDRP pilot strongly suggest this is a pivotal trial to support a Biologics License Application (BLA) for full FDA approval in 2028. Autoimmune CAR-T is the hottest sub-sector in all of biotech right now. Let's wait for the corporate PR to ignite the skyrocketing of the stock price. GO GO GO $FATE $ALLO $CABA $ALT $LABU Show me the money🤑🤑🤑Cheers!!!
1 · Reply
chicJ
chicJ May. 9 at 4:00 AM
$ALLO move
0 · Reply
Latest News on ALLO
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 6, 2026, 8:30 AM EDT - 6 days ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

2026-04-21T12:50:39.000Z - 21 days ago

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Apr 21, 2026, 8:30 AM EDT - 21 days ago

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Apr 20, 2026, 8:30 AM EDT - 22 days ago

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Apr 16, 2026, 4:01 PM EDT - 26 days ago

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

2026-04-16T10:18:20.000Z - 27 days ago

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

2026-04-16T09:26:14.000Z - 27 days ago

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

2026-04-15T16:06:54.000Z - 27 days ago

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

Unusually active option classes on open April 15th

2026-04-15T13:40:27.000Z - 27 days ago

Unusually active option classes on open April 15th

AEO BULL CHGG EOSE IMMP PAAS QUBT

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Apr 15, 2026, 8:30 AM EDT - 27 days ago

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00

2026-04-15T02:00:15.000Z - 4 weeks ago

Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 14, 2026, 9:50 PM EDT - 4 weeks ago

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

2026-04-14T11:51:26.000Z - 4 weeks ago

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

Allogene Therapeutics price target raised to $9 from $7 at Baird

2026-04-14T11:46:22.000Z - 4 weeks ago

Allogene Therapeutics price target raised to $9 from $7 at Baird

Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

2026-04-14T10:15:55.000Z - 4 weeks ago

Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright

Allogene Therapeutics price target raised to $8 from $5 at Citizens

2026-04-14T09:50:12.000Z - 4 weeks ago

Allogene Therapeutics price target raised to $8 from $5 at Citizens

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

2026-04-13T20:45:37.000Z - 4 weeks ago

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

CLLS

Allogene Therapeutics announces $175M common stock offering

2026-04-13T20:35:10.000Z - 4 weeks ago

Allogene Therapeutics announces $175M common stock offering

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Apr 13, 2026, 4:01 PM EDT - 4 weeks ago

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics Transcript: Study result

Apr 13, 2026, 8:30 AM EDT - 4 weeks ago

Allogene Therapeutics Transcript: Study result

Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial

2026-04-13T12:27:31.000Z - 4 weeks ago

Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial

NTRA

Allogene Therapeutics data from ALPHA3 trial a ‘home run,’ says TD Cowen

2026-04-13T12:15:54.000Z - 4 weeks ago

Allogene Therapeutics data from ALPHA3 trial a ‘home run,’ says TD Cowen

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

NTRA

Allogene Therapeutics reports data from ALPHA3 trial

2026-04-13T11:40:41.000Z - 4 weeks ago

Allogene Therapeutics reports data from ALPHA3 trial

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Apr 13, 2026, 7:30 AM EDT - 4 weeks ago

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Apr 10, 2026, 4:02 PM EDT - 4 weeks ago

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Allogene Therapeutics price target raised to $8 from $7 at Piper Sandler

2026-03-13T12:03:27.000Z - 2 months ago

Allogene Therapeutics price target raised to $8 from $7 at Piper Sandler

Allogene Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 2 months ago

Allogene Therapeutics Earnings Call Transcript: Q4 2025

Allogene Therapeutics reports Q4 EPS (17c), consensus (22c)

2026-03-12T20:21:38.000Z - 2 months ago

Allogene Therapeutics reports Q4 EPS (17c), consensus (22c)

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Mar 12, 2026, 4:02 PM EDT - 2 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Allogene Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 2 months ago

Allogene Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Mar 2, 2026, 8:30 AM EST - 2 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 12:15 PM EST - 2 months ago

Allogene Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Feb 5, 2026, 8:30 AM EST - 3 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Jan 8, 2026, 8:30 AM EST - 4 months ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Dec 15, 2025, 5:39 PM EST - 5 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

CLLS

Allogene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:00 PM EST - 5 months ago

Allogene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 5:00 AM EST - 6 months ago

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Allogene Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 4:30 PM EST - 6 months ago

Allogene Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Allogene Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 6 months ago

Allogene Therapeutics Earnings Call Transcript: Q3 2025

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 6, 2025, 4:05 PM EST - 6 months ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Nov 3, 2025, 9:04 AM EST - 6 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Citi's SMID Call Series 2025

Oct 2, 2025, 1:00 PM EDT - 7 months ago

Allogene Therapeutics Transcript: Citi's SMID Call Series 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 9 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics Earnings Call Transcript: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 9 months ago

Allogene Therapeutics Earnings Call Transcript: Q2 2025

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Transcript: Study Result

Aug 1, 2025, 11:00 AM EDT - 10 months ago

Allogene Therapeutics Transcript: Study Result

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 1 year ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 12:30 PM EDT - 1 year ago

Allogene Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 1 year ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q1 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 1 year ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 1 year ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q4 2024

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Allogene Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 1 year ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 1 year ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 3:20 PM EST - 1 year ago

Allogene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Allogene Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Allogene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Allogene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Dec 2, 2024, 11:00 AM EST - 1 year ago

Allogene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 6:30 AM EST - 1 year ago

Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:35 AM EST - 1 year ago

Allogene Therapeutics Transcript: Stifel 2024 Healthcare Conference

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q3 2024

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Transcript: Goldman Sachs Cell Therapy Day

Oct 1, 2024, 1:00 PM EDT - 1 year ago

Allogene Therapeutics Transcript: Goldman Sachs Cell Therapy Day

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics Transcript: Baird 2024 Global Healthcare Conference

Sep 11, 2024, 9:40 AM EDT - 1 year ago

Allogene Therapeutics Transcript: Baird 2024 Global Healthcare Conference

Allogene Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 10:00 AM EDT - 1 year ago

Allogene Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Allogene Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Allogene Therapeutics Earnings Call Transcript: Q2 2024

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 28, 2024, 12:30 PM EDT - 2 years ago

Allogene Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 8:30 AM EDT - 2 years ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

Allogene Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 15, 2024, 11:00 AM EDT - 2 years ago

Allogene Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Allogene Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 5:00 PM EDT - 2 years ago

Allogene Therapeutics Earnings Call Transcript: Q1 2024

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:47 PM EDT - 2 years ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Quant_Builder
Quant_Builder May. 13 at 11:45 AM
quant-builder.ai Healthcare Individual Stocks Moving - $IYH Another Model I have been trading the past couple of weeks. The IYH has been stuck at a post March low, but individuals have been moving and the sector looks like it's trying to break out. First image is picks for today and current positions. Second image its 30 day history. Avg. Confidence, Number of Picks, Equity Curve assuming 1% positions. These are part of a broader portfolio $HUM $UNH $ALLO $ELV
0 · Reply
AS1980
AS1980 May. 12 at 7:48 PM
$ALLO fckn misery
0 · Reply
BioFlare
BioFlare May. 12 at 4:03 PM
$ALLO I don't really understand why people keep complaining about the dilution still...Its done. Allo should now have money to keep it lasting for a while, bigger investors, and bigger appeal to the bigger huge bio companies. Yes, the shares were sold for 2$, but its not as if the price wasn't rolling at around 2$ before and after the dilution... At the end of the day, the early data is good. Think ahead
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 12 at 5:13 AM
$FATE had successfully treated 8+ patients in Regimen A (Less-Intensive Chemo). The outcomes here were spectacular, with patients achieving complete drug-free remissions (cures). The 100% response rate (3 out of 3) today on the first 3 patients from Regimen B (No Chemo / Background Therapy) is an absolute clinical triumph as proof of concept. With DL1 achieved a 100% response without chemo and the Phase 2 pivotal trial clearance by the FDA, hold strong and you will get rewarded. GO GO GO $FATE $ALLO $CABA $KYTX $LABU
1 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 12 at 3:51 AM
$FATE The fact that B-cell depletion lasted 12 months and occurred in secondary lymphoid tissue (nasopharyngeal) is a signature of CAR-T activity, not background steroids. The FDA's selection of Fate for the CDRP pilot suggests they are satisfied that the signal is coming from FT819, not the background drugs. Hope the management will announce that the RECLAIM-LN Phase 2 will be chemo-free and, most importantly, a registrational pivotal trial tomorrow. Cheers! $FATE $ALLO $CABA $KYTX
0 · Reply
Unburdened
Unburdened May. 11 at 4:34 PM
$ALLO Can't hold a gain if we wanted too. So glad you diluted the shit out of us for $2.00 per share. How does it feel to be A&$ F$&@!$ by Goldman and shares stolen from you?? You diluted us at $2.00 when it was trading at $2.65 BEFORE the supposed "great data". What a bunch of 🤡🤡🤡's.
0 · Reply
AS1980
AS1980 May. 11 at 1:37 PM
$ALLO why so fckn pathetic
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 11 at 1:02 PM
$FATE Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting. Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire. Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; Preclinical data for FT836 shows effective elimination of broad range of cancers in synergy with SOC treatments. Go for moon shoot $FATE !!! $CABA $ALLO $ALT $LABU
1 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 10 at 12:36 AM
$FATE A trial cannot be posted to ClinicalTrials.gov for a Phase 2 study unless the FDA has cleared the IND protocol. This means the FDA has officially authorized FATE to expand FT819 into Lupus Nephritis (LN) with a "Single-Arm" Design. While the trial is labeled "Phase 2," the single-arm nature and its timing alongside the CDRP pilot strongly suggest this is a pivotal trial to support a Biologics License Application (BLA) for full FDA approval in 2028. Autoimmune CAR-T is the hottest sub-sector in all of biotech right now. Let's wait for the corporate PR to ignite the skyrocketing of the stock price. GO GO GO $FATE $ALLO $CABA $ALT $LABU Show me the money🤑🤑🤑Cheers!!!
1 · Reply
chicJ
chicJ May. 9 at 4:00 AM
$ALLO move
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 8 at 1:21 AM
$FATE This is exactly the reason why I would acquire $FATE if I were the boss of a big biopharma in cellular therapy. $1B first and $10 the next. Show me the monty 🤑🤑🤑$FATE $CABA $ALLO
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 7 at 3:43 PM
$FATE any shorts here will get toasted and become desperate in the days to come. GO GO GO $FATE $CABA $ALLO , Cheers 🥂🥂🥂🍾
0 · Reply
Quant_Builder
Quant_Builder May. 7 at 12:06 PM
quant-builder.ai Healthcare Model has just been on fire. Big wins yesterday in $ALLO (top pick yesterday) as well as got taken out of $ATYR (almost lost a finger) Those two are top picks again today. I still own ALLO and others from yesterday. Other usual notables, $UNH $HUM $ELV Free Demo at quant-builder.ai/learn
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 6 at 4:20 PM
$FATE is none stoppable, every correction is the buying opportunity, hold strong while you can, institution holders own more than 95% of this stock, insiders another 5%, there will be a insane bull run 🐂 if the FDA approval drops anytime soon. GO GO GO, $FATE $ALLO $CABA
1 · Reply
Travelling
Travelling May. 6 at 2:47 PM
$ALLO Sold recently at 4.08, buying a bit to hold
0 · Reply
StijnRR
StijnRR May. 6 at 1:46 PM
$ALLO https://finance.yahoo.com/sectors/healthcare/articles/allogene-therapeutics-report-first-quarter-123000086.html
0 · Reply
Abzdolla
Abzdolla May. 6 at 10:20 AM
$XBIO Everyone’s focused on the CAR-T data itself. I’m focused on who might need it. If DNase/NET targeting really improves persistence, trafficking, and exhaustion… this becomes bigger than a one-drug story. $GILD /Kite, $BMY $AUTL , $ALLO all have reasons to watch this closely. Tiny valuation. Unique angle. ASCO timing. Feels like something strategic may already be brewing behind the scenes.
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 6 at 1:53 AM
$FATE FT819 was selected for the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program, a highly selective initiative with no more than nine proposals accepted annually. This is also a massive de-risking event and validates the iPSC platform as a commercial-ready standard. By providing "enhanced product-specific FDA engagement," the agency is effectively hand-holding Fate through the manufacturing scale-up. Next nuke to drop: FDA approval of the Phase 2 registrational pivotal clinical trial. Show me the money, cheers!🤑🤑🤑 $CABA $ALLO
0 · Reply
microdine
microdine May. 5 at 4:52 PM
$ALLO trash
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 5 at 1:21 PM
$FATE This is huge, not only fast approval, but also readiness for commercial distribution! GO GO GO, $FATE $CABA $ALLO
0 · Reply
Baldchinese
Baldchinese May. 5 at 9:05 AM
$ALLO Should be atleast 3$ per share
0 · Reply
AlphaOfBiotech
AlphaOfBiotech May. 5 at 2:25 AM
$FATE earnings estimated May 6 - May 14, 2026, pending FDA approval of the registrational (pivotal) trial for FT819 in SLE under RMAT designation anytime, three presentations in ASGCT annual meeting May 11–15, 2026. May will be a Christmas wish come true time for $FATE $CABA $ALLO . Cheers!!!🤑🤑🤑 FT819 Poster (May 12): Clinical data on FT819 driving B-cell remodeling in SLE without conditioning chemotherapy. FT836 Poster (May 13): Preclinical data for pan-tumor targeting CAR T-cells. FT839 Oral (May 14): Presentation on next-generation dual-targeting CAR T-cells for autoimmunity and oncology.
0 · Reply